Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya

Vaccine

Volumn 30, Issue SUPPL. 1, 2012, Pages

  Feikin, Daniel R ^a   Laserson, Kayla F ^a   Ojwando, Joel ^a   Nyambane, Geoffrey ^a   Ssempijja, Victor ^a   Audi, Allan ^a   Nyakundi, Daveline ^a   Oyieko, Janet ^a   Dallas, Michael J ^b   Ciarlet, Max ^b,d   Neuzil, Kathleen M ^c   Breiman, Robert F ^a  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b MERCK RESEARCH LABORATORIES   (United States)

^c PATH   (United States)

^d NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

Author keywords

Kenya; Rotavirus; Vaccine efficacy; Vaccine probe

Indexed keywords

ORAL REHYDRATION SOLUTION; PLACEBO; ROTAVIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GASTROENTERITIS; GENOTYPE; HEALTH CARE FACILITY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; KENYA; MAJOR CLINICAL STUDY; MALE; MALI; MULTICENTER STUDY; PHYSICAL EXAMINATION; POPULATION RESEARCH; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; WORLD HEALTH ORGANIZATION;

ADMINISTRATION, ORAL; DOUBLE-BLIND METHOD; FECES; FEMALE; GASTROENTERITIS; GENOTYPE; HIV INFECTIONS; HUMANS; INCIDENCE; INFANT; KENYA; MALE; PLACEBOS; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINATION; VACCINES, ATTENUATED;

EID: 84859947997     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.043     Document Type: Article

References (43)

1. Black R.E., Cousens S., Johnson H.L., Lawn J.E., Rudan I., Bassani D.G., et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010, 375(9730):1969-1987.
2. Boschi-Pinto C., Velebit L., Shibuya K. Estimating child mortality due to diarrhoea in developing countries. Bull World Health Organ 2008, 86(9):710-717.
3. Parashar U.D., Burton A., Lanata C., Boschi-Pinto C., Shibuya K., Steele D., et al. Global mortality associated with rotavirus disease among children in 2004. J Infect Dis 2009, 200(Suppl. 1 (200)):S9-S15.
4. Tate J.E., Rheingans R.D., O'Reilly C.E., Obonyo B., Burton D.C., Tornheim J.A., et al. Rotavirus disease burden and impact and cost-effectiveness of a rotavirus vaccination program in Kenya. J Infect Dis 2009, 200(Suppl. 1 (200)):S76-S84.
5. Meeting of the immunization Strategic Advisory Group of Experts, April 2009-conclusions and recommendations. Wkly Epidemiol Rec 2009, 84(23):220-236.
6. Madhi S.A., Cunliffe N.A., Steele D., Witte D., Kirsten M., Louw C., et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010, 362(4):289-298.
7. Armah G.E., Sow S.O., Breiman R.F., Dallas M.J., Tapia M.D., Feikin D.R., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376(9741):606-614.
8. National AIDS and STI Control Programme MoH, Kenya. Kenya AIDS Indicator Survey 2007: Preliminary Report. Nairobi, Kenya; July 2008.
9. Adazu K., Lindblade K.A., Rosen D.H., Odhiambo F., Ofware P., Kwach J., et al. Health and demographic surveillance in rural western Kenya: a platform for evaluating interventions to reduce morbidity and mortality from infectious diseases. Am J Trop Med Hyg 2005, 73(6):1151-1158.
10. Zaman K., Dang D.A., Victor J.C., Shin S., Yunus M., Dallas M.J., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376(9741):615-623.
11. Integrated Management of Childhood Illness [database on the Internet]. World Health Organization; 2008 [cited January 28, 2009]. Available from: http://whqlibdoc.who.int/publications/2008/9789241597289_eng.pdf.
12. Laserson K.F., Nyakundi D., Feikin D.R., Nyambane G., Cook E., Oyieko J., et al. Safety of the RotaTeq® rotavirus vaccine in Kenya, including among HIV-infected infants. Vaccine 2012, 30(Suppl. 1):A61-A70.
13. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354(1):23-33.
14. Ruuska T., Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990, 22(3):259-267.
15. Clark H.F., Borian F.E., Bell L.M., Modesto K., Gouvea V., Plotkin S.A. Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season. J Infect Dis 1988, 158(3):570-587.
16. Brooks J.T., Ochieng J.B., Kumar L., Okoth G., Shapiro R.L., Wells J.G., et al. Surveillance for bacterial diarrhea and antimicrobial resistance in rural western Kenya, 1997-2003. Clin Infect Dis 2006, 43(4):393-401.
17. DiStefano D.J., Kraiouchkine N., Mallette L., Maliga M., Kulnis G., Keller P.M., et al. Novel rotavirus VP7 typing assay using a one-step reverse transcriptase PCR protocol and product sequencing and utility of the assay for epidemiological studies and strain characterization, including serotype subgroup analysis. J Clin Microbiol 2005, 43(12):5876-5880.
18. Gilchrist M.J., Bretl T.S., Moultney K., Knowlton D.R., Ward R.L. Comparison of seven kits for detection of rotavirus in fecal specimens with a sensitive, specific enzyme immunoassay. Diagn Microbiol Infect Dis 1987, 8(4):221-228.
19. Cornfield J. A statistical problem arising from retrospective studies. Berkeley: University of California; 1956 [Contract No.: Document Number].
20. Conclusions and recommendations from the immunization strategic advisory group. Wkly Epidemiol Rec 2006, 81(1):2-11.
21. Mwenda J.M., Ntoto K.M., Abebe A., Enweronu-Laryea C., Amina I., McHomvu J., et al. Burden and epidemiology of rotavirus diarrhea in selected African countries: preliminary results from the African Rotavirus Surveillance Network. J Infect Dis 2010, 202(Suppl. (202)):S5-S11.
22. Cutts F.T., Zaman S.M., Enwere G., Jaffar S., Levine O.S., Okoko J.B., et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in the Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005, 365(9465):1139-1146.
23. Gessner B.D., Sutanto A., Linehan M., Djelantik I.G., Fletcher T., Gerudug I.K., et al. Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe trial. Lancet 2005, 365(9453):43-52.
24. Burton D.C., Flannery B., Onyango B., Larson C., Alaii J., Zhang X., et al. Healthcare-seeking behaviour for common infectious disease-related illnesses in rural Kenya: a community-based house-to-house survey. J Health Popul Nutr 2011, 29(1):61-70.
25. Sacarlal J., Nhacolo A.Q., Sigauque B., Nhalungo D.A., Abacassamo F., Sacoor C.N., et al. A 10 year study of the cause of death in children under 15 years in Manhica, Mozambique. BMC Public Health 2009, 9(67):67.
26. Armstrong Schellenberg J.R., Adam T., Mshinda H., Masanja H., Kabadi G., Mukasa O., et al. Effectiveness and cost of facility-based Integrated Management of Childhood Illness (IMCI) in Tanzania. Lancet 2004, 364(9445):1583-1594.
27. Burgert C.R., Bigogo G., Adazu K., Odhiambo F., Buehler J., Breiman R.F., et al. Impact of implementation of free high-quality health care on health facility attendance by sick children in rural western Kenya. Trop Med Int Health 2011, 29(10):1365-3156.
28. Hayes J.A. Hedging opportunities in health care. Health Care Strateg Manage 1990, 8(3):12-14.
29. Taffa N., Chepngeno G. Determinants of health care seeking for childhood illnesses in Nairobi slums. Trop Med Int Health 2005, 10(3):240-245.
30. Cunliffe N.A., Gondwe J.S., Kirkwood C.D., Graham S.M., Nhlane N.M., Thindwa B.D., et al. Effect of concomitant HIV infection on presentation and outcome of rotavirus gastroenteritis in Malawian children. Lancet 2001, 358(9281):550-555.
31. Nakawesi J.S., Wobudeya E., Ndeezi G., Mworozi E.A., Tumwine J.K. Prevalence and factors associated with rotavirus infection among children admitted with acute diarrhea in Uganda. BMC Pediatr 2010, 10(69):69.
32. Steele A.D., Cunliffe N., Tumbo J., Madhi S.A., De Vos B., Bouckenooghe A. A review of rotavirus infection in and vaccination of human immunodeficiency virus-infected children. J Infect Dis 2009, 200(Suppl. 1 (200)):S57-S62.
33. van Eijk A.M., Brooks J.T., Adcock P.M., Garrett V., Eberhard M., Rosen D.H., et al. Diarrhea in children less than two years of age with known HIV status in Kisumu, Kenya. Int J Infect Dis 2010, 14(3):e220-e225.
34. Moss W.J., Clements C.J., Halsey N.A. Immunization of children at risk of infection with human immunodeficiency virus. Bull World Health Organ 2003, 81(1):61-70.
35. Velazquez F.R., Matson D.O., Calva J.J., Guerrero L., Morrow A.L., Carter-Campbell S., et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996, 335(14):1022-1028.
36. Armah G.E., al E. Immunogenicity of the pentavalent rotavirus vaccine in African infants. Vaccine 2012, 30(Suppl. 1):A86-A93.
37. Madhi S.A., al E. Rotavirus vaccine in South African children: a randomized double blind controlled trial on immunogenicity and efficacy during the first two years of life. Vaccine 2012, 30(Suppl. 1):A44-A51.
38. Suharyono, Simanjuntak C., Witham N., Punjabi N., Heppner D.G., Losonsky G., et al. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. Lancet 1992, 340(8821):689-694.
39. Bernstein D.I., Smith V.E., Sander D.S., Pax K.A., Schiff G.M., Ward R.L. Evaluation of WC3 rotavirus vaccine and correlates of protection in healthy infants. J Infect Dis 1990, 162(5):1055-1062.
40. Ciarlet M., Sani-Grosso R., Yuan G., Liu G.F., Heaton P.M., Gottesdiener K.M., et al. Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine. Pediatr Infect Dis J 2008, 27(10):874-880.
41. Patel M., Shane A.L., Parashar U.D., Jiang B., Gentsch J.R., Glass R.I. Oral rotavirus vaccines: how well will they work where they are needed most?. J Infect Dis 2009, 200(Suppl. 1 (200)):S39-S48.
42. Siegrist C.A. Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine 2003, 21(24):3406-3412.
43. Weinberger D.M., Malley R., Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011, 12:12.